Taken together, our results suggest that MSH2 promotes glioma stemness and chemoresistance by sustaining Wnt/β‐catenin activity, thereby positioning MSH2 as a potential therapeutic target in glioma treatment strategies aimed at eradicating CSCs and overcoming drug resistance. Here, MSH2 is linked to central nervous system cancer.